Viral Entry Inhibitors Derived From Botanicals
US-2025288632-A1 · Sep 18, 2025 · US
Anti-esophageal cancer compound and method of use thereof
US9655913B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9655913-B2 |
| Application number | US-201615190367-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 23, 2016 |
| Priority date | Jun 23, 2015 |
| Publication date | May 23, 2017 |
| Grant date | May 23, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the bioactive components with the anti-proliferative property. In particular, the invention relates to one flavonol compound isolated from the root of Lasia spinosa Linn. Thwait or chemically synthesized and its specific anticancer/antitumor activity. This invention has a specific application in treating human esophageal cancer.
First claim
Opening claim text (preview).
We claim: 1. A method for inhibiting the growth of an esophageal tumor in a subject in need thereof by administering to said subject a composition comprising an effective amount of a compound comprising a structural unit of 2. The method according to claim 1 wherein the effective amount of the compound is no more than 2.43 mg/kg/day. 3. The method according to claim 1 wherein the subject in need thereof is a human. 4. The method according to claim 1 wherein the compound is administered via intraperitoneal injection.
Assignees
Inventors
Classifications
- A61K36/888Primary
Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage · CPC title
having two or more such linkages · CPC title
3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9655913B2 cover?
- The present invention relates to the bioactive components with the anti-proliferative property. In particular, the invention relates to one flavonol compound isolated from the root of Lasia spinosa Linn. Thwait or chemically synthesized and its specific anticancer/antitumor activity. This invention has a specific application in treating human esophageal cancer.
- Who is the assignee on this patent?
- Univ Hong Kong Baptist Univ, Changshu Hkbu Tech Company Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K36/888. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).